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ABSTRACT
Preeclampsia is one of the main contributors on morbidity and mortality 
of mother and fetus. Imbalance of body antioxidants and oxidants has a role 
on endothelial destruction causing endothelial dysfunction which leads to 
preeclampsia. L-arginine administration is indicated to be able to fix the 
remodelling process of hepatocytes which was damaged on preeclampsia. 
The aim of this study was to investigate the effect of L-arginine on hepatocyte 
cells damage on mouse (Mus musculus) model of preeclampsia. Experimental 
study was conducted in the Experimental Animal Warehouse and Biomedical 
Laboratory, Faculty of Veterinary Medicine, Airlangga University, Surabaya. A 
total of 30 pregnant mice were divided into three groups with 10 mice in each 
group i.e. normal, preeclampsia model and preeclampsia model with L-arginine 
therapy pregnant mice. Preparates were taken from dissected mice liver, with 
prior paraffin block and were then stained with hematoxylin-eosin. Results 
were analyzed semi quantitatively with Manja Roenigk hepar histology scoring 
method. Data were analyzed using Kruskal-Wallis and Man-Whitney test. Mean 
of hepar histopathology score of preeclampsia model with L-arginine therapy 
(40.80±1.17/µm2) was significantly lower compared with preeclampsia model 
pregnant mice (58.80±4.23/µm2) (p<0.05), however it was significantly higher 
compared with normal pregnant mice (18.40±2.41/µm2) (p<0.05). It was indicated 
that the L-arginine therapy on preeclampsia mouse model can reduce the score 
of hepar histopathology. In conclusion, L-arginine administration can reduce the 
hepatocyte cells damage of mouse due to preeclampsia.
ABSTRAK
Preeklamsia merupakan salah satu contributor utama morbiditas dan mortalitas 
pada ibu dan janin. Ketidakseimbangan antioksidan dan oksidan tubuh 
berperan terjadinya kerusakan endotel yang menyebabkan disfungsi endotel 
dan terjadinya preeklamsia. Pemberian L-arginine diduga memperbaiki proses 
remodeling sel hepatosit hepar yang rusak pada preeklamsia. Penelitian ini 
bertujuan untuk mengkaji pengaruh pemberian L-arginine terhadap perbaikan 
kerusakan sel hepatosit hepar yang dinilai dari skor histopatologi hepar 
model mencit (Mus musculus) preeklamsia. Penelitian dilakukan di Kandang 
Hewan Percobaan dan Laboratorium Biomedik, Fakultas Kedokteran Hewan, 
Universitas Airlangga, Surabaya. Sebanyak 30 ekor mencit bunting dibagi 
dalam 3 kelompok dengan masing-maing kelompok 10 ekor yaitu kelompok 
mencit bunting normal, model preeclampsia dan model preeclampsia dengan 
terapi L-arginin. Pengambilan preparat dilakukan pada heparmencit yang 
sebelumnya telah dibedah dan dilakukan blok parafin untuk kemudian diberi 
pewarna hematoxylin-eosin. Hasil dianalisis secara semi kuantitatif menurut 
metode skor histopatologi hepar Manja Roenigk. Analisa data menggunakan uji 
Kruskal-Wallis dan Man-Whitney. Rerata skor histopatologi hepar model mencit 
preeclampsia yang diterapi L-arginin (40,80±1,17/µm2) lebih rendah secara nyata 
dibandingkan dengan model mencit preeclampsia (58,80±4,23/µm2) (p<0,05), 
namun demikian lebih tinggi secara nyata dibandingkan dengan tikus bunting 
normal (18,40±2,41/µm2) (p<0,05). Hal ini menunjukan terapi L-arginin dapat 
menurunkan skor histopatologi hepar pada model mencit preeclampsia. Dapat 
disimpulkan, pemberian L-arginin dapat menurunkan kerusakan hepatosit 
mencit akibat preeclampsia.
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INTRODUCTION
Preeclampsia is a serious 
complication in pregnancy characterized 
by elevated blood pressure and 
proteinuria on the 20th week of pregnancy. 
Preeclampsia prevalence ranges from 
5-8% from pregnancy population, but 
it increases to 10-15% in pregancy with 
high risk.1 Preeclampsia complication 
causes approximately 50.000 maternal 
death each year.2  In Indonesia, 30-40% 
preeclampsia becomes the cause of 
maternal death and 30-50% becomes the 
cause of perinatal death. In Dr. Moewari 
Generah Hospital, Surakarta, Central Java 
maternal death caused by preeclampsia 
was 67.6% from 37 preeclampsia case 
from 1956 births in 2008.3
Endothelial dysfunction in 
preeclampsia increases blood vessels 
resistence, platelet aggregation, and 
coagulation system activation. These 
factors are related to abnormal 
placentation marked by cytotrophoblast 
dysfunction and inadequate spiralis 
artery invasion on myometrium. 
This initiates vasoconstriction and 
hypoperfusion causing ischaemia and 
hypoxia on placenta.4
Preeclampsia is also linked to 
elevation of oxidative stress. Reactive 
oxygen type also known as reactive 
oxygen species (ROS) plays important role 
in this process. Reactive oxygen works as 
placenta cellular growth, differentiation, 
apoptosis, and also the out put of the 
pregnancy itself. Relative hypoxia 
on placenta is linked to inadequate 
uteroplacenta circulation. These factors 
will cause maternal endotel damage.5
Nowadays, experts propose a 
hypothesis of primer dysfunction of 
preeclampsia is caused by relative 
deficiency of available nitric oxide (NO), 
and oversaturation of peroxynitrite 
(ONOO). The combination of NO 
deficiency and elevated ONOO directly 
and indirectly initiate physiologic 
change and serologic change related 
to preeclampsia, platelet dysfunction, 
thromboxane (TXA) elevation and 
endothelin also reduction of prostacyclin 
(PGI2). NO is an endogen vasodilator 
synthesized from non essential amino 
acid L-arginine with mediation of nitric 
oxide synthase (NOS). Oxydative stress 
is opposed to be the key factor of the 
occurrence of preeclampsia, so that 
the administration of antioxidant on 
pregnant woman during pregnancy is 
expected to delay or prevent the onset of 
preeclampsia.6
Endothel dysfunction causing 
reduction of vasodilator molecule 
formation like NO is one of the vasoactive 
mediator of endothel. During pregnancy 
with preeclampsia, there is an increase 
on assymetric dimethyl arginine (ADMA) 
synthesis. ADMA is an endogen inhibitor 
of NOS, reducting NO synthesis. 
L-arginine is a NO precursor amino acid. 
Enzymatic pathway of L-arginine affects 
the formation of NOS. In patients with 
elevated ADMA, L-arginine compete 
with ADMA for NOS, so that the number 
of NO elevated.7
Mice were used (Mus musculus) as 
animal model of preeclampsia due to 
mice are the most common animal to 
be used in bimoedic experiments,  have 
a genetical similarities with human and 
have an ability to adapt in laboratory 
environment.3 Hepatal damage in 
relation with preeclampsia varies from 
light elevation of hepatal enzyme to 
broad bleeding under liver capsule 
(hematoma subcapsular) and hepatic 
rupture. The last two conditions are 
linked to HELLP syndrome. Hepatal 
lesion seen on biopsy and autopsy 
includes periportal bleeding, ischaemic 
lesion, and fibrin deposit.8 On severe 
preeclampsia, changes may be found 
in hepar function and integrity test. 
Periportal bleeding necrosis in the edge 
of hepatal lobules seem to be the reason 
of elevated serum hepatal enzyme.9  If 
bleeding occurs on periportal cells of the 
perifer lobule, hepatocyte cell necrosis 
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will happen. The bleeding will broaden 
into the under hepar capsule called 
subcapsular hematoma.10
L-arginine have an important role 
in L-arginine-nitric oxide pathway on 
preeklampsia. Several studies reported 
that the NO production elevates in 
normal pregnancy. On mice, cyclic 
guanosine monophosphate (cGMP, a 
NO second messenger) level on plasma 
and urine also nitrite/nitrate urine 
level, NO metabolite, and indicator 
of NO production in the body, will 
elevate during pregnancy.11  This study 
was aimed to investigate the effect of 
L-arginine administration on hepatocyte 




The study was conducted after an 
Ethical Clearance (number 648-KE) from 
Reseach Ethics Committee in Faculty 
of Veterinary Medicine, Airlangga 
University, Surabaya Indonesia was 
obtained. A total of 30 female Swiss mice 
aged 12 week with body weight 20-25 g 
obtained from Veterina Farma, Surabaya 
were used in this study.
Impregnate mice were conducted 
by synchronizing female mice lust 
with injecting 5 IU of pregnant more 
serum gonadotropin (PMSG) hormone 
followed by injecting 5 IU of human 
chorionic gonadotropin (hCG) after 48 h 
later. The female mice were then mated 
monomatedly by place each synchronized 
mouse into a cage with one male mouse 
aged 28 week with body weigh ± 60 g. 
Furthermore, 17 h after mated pregnant 
mice were diagnosed if copulatory plug 
(a plug on mice’s vagina from cervix to 
vulva) was observed. The 30 pregnant 
Swiss mice were then divided into three 
groups with 10 mice in each group i.e. 
normal pregnancy (G1), preeclampsia 
model  (G2) and preeclampsia model 
with L-arginine therapy (G3)  mice.12
Protocol of study
On the 1st until 4th day of 
pregnancy, mice of G2 and G3 were 
injected anti Qa-2 10 ng IV (Mouse Qa-
2® - Qa Lymphocyte Antigen 2 Region - 
MyBioSource TM).3 Following on 7 to 15th 
day, mice of G3 were given L-arginine 
at dose of 200 mg/kg body weigh/oral/
day (# 400145/L-Arginine Free Base® 
50 gr, Dyets Inc. TM). On the 16th day of 
pregnancy termination was conducted in 
all three groups of mice, being an analog 
of a 2nd trimester of human pregnancy 
where preeclampsia manifestation 
emerges in human. The mice were 
eutanated with ketamine and continued 
with necropsy. After all abdominal 
cavity were dissected and visible, liver 
was taken and moved into a pot of netral 
buffer formalin 10% for fixation. The 
indicator used to measure the successful 
rate of modeling preeclampsia was by 
looking at the level of hepatocyte cell 
repair to normal.
Preparates were made for 
histological examination, where fixated 
hepar was cuted and moved into a 
specimen plastic pot. Preparates were 
then colored with hematoxylin-eosin 
(HE). The preparates were observed 
under the microscope of Nikon Eclipse 
Ci with a magnification of 400x. Hepar 
histopathological change was scored 
with a Manja Roenigk scoring model as 
presented on  TABLE 1.
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The number of cell damage was 
calculated on 5 field of view in each 
preparates paraffin block. The parameter 
for determining hepatic cell damage was 
conducted by comparing the structure 
change of the mice hepar-hostpathology 
in 3 groups, by finding signs of 
histopathological changes including 
degeneration and necrosis. Numbers of 
cells changing on each preparates were 
noted, then calculated to discover the 
scoring.14,15 In this experiment, one slide 
was prepared in each mouse, so that 
there were 30 slides in maximum. All 
experimentals process were performed 
in Experimental Animal Warehouse 
and Biomedical Laboratory, Faculty 
of Veterinary, Airlangga University, 
Surabaya, Indonesia.
Statistical analysis
Data were presented as mean ± 
standard deviation (SD) and  analyzed 
using SPSS (Software Package for Social 
Science) 21. Results were calculated 
semiquantitatively with Manja Roenigk 
hepar histology scoring method. Data 
were tested nonparametrically using 
Kruskal-Wallis test. If there was any 
significant differences, a Mann-Whitney 
test was performed. A p value <0.05 with 
confident interval 95% was considered 
significant.
RESULTS
FIGURE 1 presents hepar 
histopathology of all groups. Normal 
pregnant mice (G1) showed clear margin 
of sinusoid, hepatocyte cells structured 
radially, and degeneration and necrosis 
of cells not found, and cells clearly 
visible. On mice model preeclampsia 
(G2) showed and hepatocyte cells with 
hidropic degeneration (yellow arrow 
1), accumulation of inflammation cell 
(blue arrow 2), hepar sinusoid not 
clearly visible, cells overlapping and 
accumulated, necrosis hepatocyte cells 
not found indicating hepatocyte cells 
damage. On mice model preeclampsia 
after L-arginine administration 
(G3) showed hepatocyte cells with 
parenchymal degeneration (arrow 3), 
space between sinusoid clearly bordered 
and hepatocyte cells looks normal and 
clearly visible indicating hepatocyte cells 
repair observed.
FIGURE 1. Comparation of hepar histopathology between musmusculus mice normal 
pregnany (G1), model preeclampsia (G2), and model preeclampsia with 
L-arginine therapy (G3).
G1 G2 G3
Mean of hepar histopathology 
score of preeclampsia model with 
L-arginine therapy (40.80±1.17/µm2) 
was significantly lower compared with 
preeclampsia model pregnant mice 
(58.80±4.23/µm2) (p<0.05). However, it 
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FIGURE 2. Mean of hepar immunochemical score. G1 vs G2 (p<0.05); 
G1 vs G3 (p<0.05) and G2 vs G3 (p<0.05)
DISCUSSION
During pregnancy under 
circumstances of increased NO 
production, endogenous synthesis of 
L-arginine is insufficient. L-arginine 
concentrations is significantly reduced 
in women with preeclampsia compared 
wih healthy women. However, it appears 
that the ratio ADMA to L-arginine, rather 
than the concentration of L-arginine, 
is more critical in determining NOS 
activity and the subsequent production 
of oxygen free radicals, thus creating a 
perpetuating of NOS dysfunction.16
Endothel dysfunction related to NO 
synthesis dysfunction is considered to 
be one of the causes of hypertension on 
pregnancy. L-arginine administration 
for pregnant woman will elevate NO 
production on peripheral vessels and 
lowered blood pressure. Moreover, it 
has been reported that administration 
of L-arginine can ameliorate artery 
hypertension, hypertention related to 
pregnancy pathology, ischaemic disease, 
circulatory failure, aterosklerosis and 
cerebral stroke.17
Nitric oxide is a free radical role in 
human physiology in many ways. Its role 
on obstetric is to help smooth muscles 
relaxation. Nitric oxide production main 
site is NOS inside endothelial cells, used 
in L-arginine circulation as a substrate. 
Therefore, the local ability of these 
amino acids is important to regulate 
the endothelial adaptive mechanisms 
that are opposed to the occurrence 
of vasoconstrictors in preeclampsia. 
L-arginine is a semi essential amino acid 
because under an increased demand, 
and inadequate endogen synthesis to 
fulfill the requirement. Vasodilatation 
failure obtained in patients with 
preeclampsia. Circulated L-arginine 
substrate on NO synthesis happens 
during pregnancy. Preliminary data 
shows L-arginine supplement on diet 
reduced preeclampsia risk during 
pregnancy with increase vasodilatation 
was significantly higher compared with 
normal pregnant mice (18.40±2.41/µm2) 
(p<0.05) (FIGURE 2). It was indicated 
that the L-arginine adminstration on 
preeclampsia mouse model can reduce 
the score of hepar histopathology score. 
However, the reducion did not achieved 
the normal condition.
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through elevation of NO.18
Oxidative stress marked with an 
imbalaced production of ROS and 
endogen antioxidant. This change may 
cause cell structure damage from any 
tissues and organs, with changing vital 
function and determining cell death. 
Latest study shows oxidative stress as 
one of the main factor in preeclampsia 
pathophysiology and may interfere all 
reproductive period on woman. Other 
study support the hypothesis of oxidative 
stress could contribute on preeclampsia 
syndrome etiology.19
L-arginine acts as NO precursor and 
turned into NO and L-citrulline by NOS. 
L-arginine administration on pregnant 
woman with preeclampsia shows 
significant decrease of blood pressure. 
A controlled random trial shows diet 
supplementation with L-arginine 
combination and antioxidant vitamin 
such as vitamin C and E linked with 
significant decrease on preeclampsia 
cases, compared to antioxidant vitamin 
alone and placebo.20
L-arginine decreases the number of 
preeclampsia cases and preeclampsia 
frequency 14.5%. Decreased risk on 
L-arginine group is estimated 26% with 
efficacy of 74%. L-arginine decreases 
incidence rate of severe preeclampsia 
significantly.20 Latest study shows that 
L-arginine decreases systolic blood 
pressure, diastolic, and mean arterial 
pressure (MAP). Even on patients with 
chronic hypertension could reduce 
antihypertension medication doses. 
Decrease of preeclampsia incidence rate 
shows pregnancy with more gestational 
age and better perinatal outcome. 
Premature births are lower in L-arginine 
group and child given birth in this group 
has higher birth weight than placebo 
group.7
L-arginine works through NOS 
pathway with inhibit NO synthesis by 
inhibit NOS inhibitor so the production 
of NO will increase and able to give an 
impact on vascular vasodilatation and 
improve hypoxia, therefore L-arginine 
might be a new therapeutic option for 
hypertension in pregnancy to prevent 
the incidence of preeclampsia in high-
risk women. 16
The mechanism of hepatic lesions 
with different etiologies begins with 
bleeding into the liver cell column due 
to arteriolar vasodilation, resulting 
in dislocation and deformation of 
hepatocytes in the stromal arm. Then in 
the advanced stage the state of persistent 
vasospasm causes gradual liver 
infarction starting from the area near the 
sinusoid and extending to the area near 
the portal vessels. Hemorrhagic changes 
occur in about 66% and necrotic changes 
in about 40% in women with eclampsia, 
which is one and a half more than in 
cases of preeclampsia. Hyalineinization 
and thrombosis of the liver have been 
obtained as evidence of DIC, but possibly 
as a result of the bleeding process.21
Cell necrosis is one of irreversible 
lesions (fibrosis, serosis) which can occur 
directly or can follow cell degeneration 
(reversible lesions; swelling and fatty 
liver). Microscopic features of necrosis 
can be picnosis, karyorrhexis, and 
karyolysis. Based on its location necrosis 
is divided into three which are focal 
necrosis, zone necrosis and submassive 
necrosis. Focal hepatic cell necrosis is 
necrosis that occurs randomly in one cell 
or a small group of cells in all regions of the 
liver lobules. This necrosis is recognized 
on biopsy through acidophilic bodies 
(councilman bodies) which are necrotic 
liver cells with a picnotic nucleus or 
lysis and pink coagulated cytoplasm. It 
can also be recognized in the liver cell 
lysis area surrounded by a collection of 
kupffer cells and inflammatory cells. 
Liver cell zone necrosis is liver cell 
necrosis that occurs in identical regions 
in all liver lobules, while submassive 
necrosis is liver cell necrosis that 
extends beyond the lobular border, often 
bridging portal areas with central veins 
(bridging necrosis).22
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L-arginine administration seems 
promising on lowering blood pressure 
and sustain pregnancy. A few studies 
showed positive result in hypertension 
effect after L-arginine administration. 
L-arginine administration is also 
reported to have a therapeutic effect on 
other pregnancy complication. However, 
other studies reported that there is 
no significant effect on L-arginine 
administration.23
In pregnancy, l-arginine insufficiency 
may occur. The ADMA concentrations, 
a competitive inhibitor of NOS, are 
increased in women with preeclampsia. 
L-arginine supplementation in diet 
can provide a source of substrate for 
the synthesis of NO during pregnancy, 
which can play a role in the process of 
vasodilation. In preeclampsia, in long 
term of L-arginine administration in low 
doses significantly decreses in maternal 
blood pressure and increases the 
bioavailability of endothelial NO.24
Other studies showed that L-arginine 
can reduce both systolic and diastolic 
blood pressure. Even patients with 
chronic hypertension significantly 
decrease the dose on antihypertensive 
medication. In subsequent studies, there 
was a decrease in the incidence of severe 
preeclampsia so as to obtain a pregnancy 
with a higher gestational age and better 
perinatal outcomes. Preterm birth was 
lower in the L-arginine group with higher 
birth weight compared to the placebo 
group.7 Therefore L-arginine can be a 
new therapeutic option for hypertension 
in pregnancy, to prevent the occurrence 
of preeclampsia especially in high-risk 
women.
CONCLUSION
L-arginine administration can 
reduce the hepatocyte cells damage of 
preeclampsia mice model.
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